SAN DIEGO, May 26, 2023 (GLOBE NEWSWIRE) —

Robbins LLP reminds investors that a shareholder has filed a class action lawsuit on behalf of persons or entities that purchased or otherwise acquired Charles River Laboratories International, Inc. CRL Common stock between May 5, 2020 and February 21, 2023. Charles River is a comprehensive, non-clinical global drug development partner on a mission to create healthier lives.

For more information please send an shape, E-mail Aaron Dumas, Jr. or call us at (800) 350-6003.

What is it about in this case: Charles River Laboratories International, Inc. (CRL) has misled investors about importing non-human primates for research

According to the complaint, on February 22, 2023, Charles River announced that it had received a subpoena from the US Department of Justice related to an ongoing investigation in cooperation with the US Fish and Wildlife Service into the supply chain and illegal importation of non-produce had. human primates for research. The company noted that it was voluntarily halting shipments of primates from Cambodia, which would negatively impact earnings for the year and reduce revenue growth by 200 basis points to 400 basis points. As a result of this news, Charles River’s share price fell $24.51, or 10%, on unusually high trading volume to close at $219.09 per share on February 22, 2023.

On March 1, 2023 The Washington Post published an article linking the investigation to an indictment against a monkey smuggling ring in November 2022. The article specifically noted that Charles River and other research organizations supply pharmaceutical companies, academic and government scientists with primates from a variety of sources, including international suppliers.

The complaint alleges that the defendants failed to disclose to investors that: (1) Charles River engaged in illegal activities related to the importation of non-human primates for research; (2) As a result, Charles River was at increased risk of criminal and…